SENS
Senseonics Holdings, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$9.01
+1.69%Oct 26, 2026, 12:00 UTC
Senseonics Holdings, Inc. initiated the first-in-human clinical study of its investigational, transmitter-free, one-year Freedom continuous glucose monitoring system.
Source:Oct 21, 2026, 12:00 UTC
Senseonics Holdings announced that it plans to release its third-quarter 2026 financial results after market close on November 9, 2026.
Source:Sep 29, 2026, 16:11 UTC
Beta Bionics integrated Senseonics' Eversense 365 continuous glucose monitor into its iLet automated insulin delivery ecosystem.
Source:Sep 14, 2026, 11:00 UTC
Senseonics Holdings announced a strategic partnership with Beta Bionics to integrate the Eversense 365 continuous glucose monitoring system with the iLet Bionic Pancreas, with a planned commercial launch in Q4 2026.
Source:Aug 6, 2026, 00:00 UTC
Senseonics Holdings reported Q2 2026 revenue of $14.5 million, a 120% increase year-over-year, with a net loss of $36.7 million.
Jun 11, 2026, 18:11 UTC
Senseonics (SENS) partners with Welldoc to develop a next-generation Eversense 365 app with Apple Health and Google Health Connect integration ahead of the U.S. launch.
Source:May 4, 2026, 00:00 UTC
Senseonics Holdings, Inc. amended its senior secured term loan facility, providing up to $140 million in loans due September 3, 2029, with an initial $35 million tranche funded at closing on May 6, 2026.